Global Cancer Generics Market Opportunities, Analysis & Forecasts, 2022: Generic Version of Blockbuster Cancer Drug & Entry of Indian Generic Cancer Drug in US - Research and Markets
DUBLIN, October 18, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Cancer Generics Market Forecast to 2022" report to their offering.
The global cancer generics market has been segmented on the basis of mode of administration into oral and injectables. Injectables are the most widely used type of cancer generics drugs. The report also highlights the major cancer generic drugs available in the global market.
Within the pharmaceutical industry, the oncology market is growing at a rapid pace owing to the rising incidences of cancer. In 2015, 15.2 Million new cancer cases were registered across the globe. This number is forecasted to increase to a value of 19.3 Million by 2025. Furthermore, the patent expiry of blockbuster cancer drugs is another major factor which is propelling the growth of the cancer generics industry.
Furthermore, the global cancer generics market has also been segmented on the basis of the major indications they are used for. According to the report, breast cancer is expected to account for the largest share in 2016 due to presence of large number of generic drugs and rising incidences of this indication.
The last section of the report discusses about the prominent players in global cancer generics market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios. The recent development of every player has also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global cancer generics market.
Key Topics Covered:
1. Analyst View
2. Research Methodology
3. Global Cancer Drugs Market Outlook 2022
3.1 Cancer Incidences
3.2 Cancer Drug Market
4. Market Drivers & Challenges
4.1 Drivers
4.1.1 Increasing Cancer Incidences
4.1.2 Strategic Collaborations
4.1.3 Growing Geriatric Population
4.1.4 Ability to Curb Healthcare Cost
4.2 Challenges
4.2.1 Growing Backlog of Generic Drug Applications
4.2.2 Counterfeit Generic Drugs
4.3 Opportunities
4.3.1 Patent Expiry of Blockbuster Oncology Drugs
4.3.2 Generic Cancer Drugs Made More Accessible to Developing Countries
5. Global Cancer Generics Market Analysis 2022
6. Global Cancer Generics Market by Mode of Administration
6.1 Oral Generics
6.2 Injectables Generics
7. Global Cancer Generics Market by Major Indications
7.1 Lung Cancer
7.2 Breast Cancer
7.3 Colorectal Cancer
7.4 Stomach Cancer
7.5 Prostate Cancer
8. Global Cancer Generics Market by Geographic Regions
9. Trends & Developments
9.1 Generic Version of Blockbuster Cancer Drug
9.2 Entry of Indian Generic Cancer Drug in US
10. Mergers & Acquisitions
11. Key Players
11.1 Fresenius Kabi AG
11.2 Pfizer Inc
11.3 Teva Pharmaceutical Industries Ltd
11.4 Mylan N.V
11.5 Sun Pharmaceutical Industries Ltd
11.6 Sandoz International GmbH - A Novartis Company
11.7 Sanofi
11.8 Dr. Reddy's Laboratories Ltd
11.9 Cipla Ltd
11.10 Apotex Inc
For more information about this report visit http://www.researchandmarkets.com/research/wxs5fv/global_cancer
Media Contact:
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article